Cargando…
The effect of SGLT2i on in-hospital acute heart failure risk in acute myocardial infarction patients—a retrospective study
BACKGROUND AND AIMS: The roles of sodium-glucose cotransporter 2 inhibitor (SGLT2i) in acute heart failure (AHF) risk after acute myocardial infarction (AMI) remain unclear. In this study, we explored the correlation between SGLT2i administration and short-term in-hospital AHF risk in AMI patients....
Autores principales: | Zhu, Yi, Zhang, Jia-li, Jin, Hong, Ji, Yuan, Wang, Fang-fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228823/ https://www.ncbi.nlm.nih.gov/pubmed/37260943 http://dx.doi.org/10.3389/fcvm.2023.1158507 |
Ejemplares similares
-
Association between the neutrophil-to-lymphocyte ratio and risk of in-hospital heart failure and arrhythmia in patients with acute myocardial infarction
por: Zhang, Jia-li, et al.
Publicado: (2023) -
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
por: Cesaro, Arturo, et al.
Publicado: (2022) -
Timing of heart failure development and clinical outcomes in patients with acute myocardial infarction
por: Kim, Hyung Yoon, et al.
Publicado: (2023) -
A plasma proteomic approach in patients with heart failure after acute myocardial infarction: insights into the pathogenesis and progression of the disease
por: Liu, Yan, et al.
Publicado: (2023) -
Uncovering Potential lncRNAs and mRNAs in the Progression From Acute Myocardial Infarction to Myocardial Fibrosis to Heart Failure
por: Wang, Shuo, et al.
Publicado: (2021)